Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIND: Botox Injection Protocols for OAB
NCT05652036Phase 4Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Jul 2022
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of botulinum toxin type A in overactive bladder (OAB) (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Participant Discomfort Related to BTX-A Injection (Numeric Pain Scale). Started Jul 2022; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05652036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652036.